Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Cellectar Biosciences Inc (CLRB)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.15-6.50%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for CLRB yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Sustain capital raising through equity offerings | The company has successfully raised capital through equity offerings to support its operations. | Intact | Failure to raise sufficient capital to support operations within next 4 quarters | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 10, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-stage biotechnology company, not an established earnings compounder. The thesis is on watch: management is advancing two programs, but recent financial performance is weak and overall confidence in the evidence is low.
The snapshot provides no valuation multiples or direct measure of market expectations, so whether CLRB is cheap or expensive versus peers is unclear. The evidence does show a weak recent earnings record, including an August 2026 miss, but does not establish how much of that is already reflected in expectations.
Near term, results may remain hard to assess because CLRB is loss-making and has a high risk of missing expectations. Management has started site activation for the iopofosine I 131 Phase 3 confirmatory trial and dosing in the CLR 125 Phase 1b trial; it plans to seek iopofosine approval in mid-2027. Cash rose to $34.0 million in 2026-Q2 after an offering, and management says it should fund operations into Q2 2027, but that does not remove funding risk beyond that period.
The multi-year view depends on clinical and regulatory progress, especially the Phase 3 trial and the planned application for iopofosine I 131. Additional CLR 125 data and the company’s ability to maintain adequate funding are also important. Near term, a guidance cut or further economic weakness could weigh on the setup, while strength among large healthcare companies may support the sector backdrop.
Over the next 1 to 3 years, CLRB’s thesis rests on trial execution, regulatory progress, and financing beyond the current cash runway; evidence remains mixed and risk is high. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The company is working to stabilize governance after director transitions. |
| Intact |
| Additional unexpected director departures or governance instability within next 4 quarters |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Reduce operating losses and net income deficits | Cellectar Biosciences is focused on managing and reducing its operating losses, which were negative $5.8 million in Q1 2026. | Broken | Operating loss or net loss worsens beyond 2026-Q1 levels over next 4 quarters | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.79 → $-1.92 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.79 | $7,648,750 | 3 / 3 |
| 2026-07-25 | $-1.79 | $7,648,750 | 3 / 3 |
| 2026-07-26 | $-1.79 | $7,648,750 | 3 / 3 |
| 2026-07-27 | $-1.79 | $7,648,750 | 3 / 3 |
| 2026-07-28 | $-1.79 | $7,648,750 | 3 / 3 |
| 2026-07-29 | $-1.79 | $7,648,750 | 3 / 3 |
| 2026-07-30 | $-1.79 | $7,648,750 | 3 / 3 |
| 2026-07-31 | $-1.79 | $7,648,750 | 4 / 4 |
| 2026-08-01 | $-1.79 | $7,648,750 | 4 / 4 |
| 2026-08-02 | $-1.79 | $7,648,750 | 4 / 4 |
| 2026-08-03 | $-1.79 | $7,648,750 | 3 / 3 |
| 2026-08-04 | $-1.79 | $7,648,750 | 3 / 3 |
| 2026-08-05 | $-1.79 | $7,648,750 | 4 / 4 |
| 2026-08-06 | $-1.79 | $7,648,750 | 3 / 3 |
| 2026-08-07 | $-1.79 | $7,648,750 | 3 / 3 |
| 2026-08-08 | $-1.79 | $7,648,750 | 4 / 4 |
| 2026-08-09 | $-1.79 | $7,648,750 | 3 / 3 |
| 2026-08-10 | $-1.79 | $7,648,750 | 3 / 3 |
| 2026-08-11 | $-1.79 | $7,648,750 | 3 / 3 |
| 2026-08-12 | $-1.79 | $7,648,750 | 4 / 4 |
| 2026-08-13 | $-1.79 | $7,648,750 | 4 / 4 |
| 2026-08-14 | $-1.79 | $7,648,750 | 3 / 3 |
| 2026-08-15 | $-1.79 | $7,648,750 | 3 / 2 |
| 2026-08-16 | $-1.79 | $7,648,750 | 3 / 2 |
| 2026-08-17 | $-1.79 | $7,648,750 | 3 / 2 |
| 2026-08-18 | $-1.79 | $7,648,750 | 3 / 2 |
| 2026-08-19 | $-1.79 | $7,648,750 | 3 / 3 |
| 2026-08-20 | $-1.79 | $7,648,750 | 3 / 3 |
| 2026-08-21 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-08-22 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-08-23 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-08-24 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-08-25 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-08-26 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-08-27 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-08-28 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-08-29 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-08-30 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-08-31 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-09-01 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-09-02 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-09-03 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-09-04 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-09-05 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-09-06 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-09-07 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-09-08 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-09-09 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-09-10 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-09-11 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-09-12 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-09-13 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-09-14 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-09-15 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-09-16 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-09-17 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-09-18 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-09-19 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-09-20 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-09-21 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-09-22 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-09-23 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-09-24 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-09-25 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-09-26 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-09-27 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-09-28 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-09-29 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-09-30 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-10-01 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-10-02 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-10-03 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-10-04 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-10-05 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-10-06 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-10-07 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-10-08 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-10-09 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-10-10 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-10-11 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-10-12 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-10-13 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-10-14 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-10-15 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-10-16 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-10-17 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-10-18 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-10-19 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-10-20 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-10-21 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-10-22 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-10-23 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-10-24 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-10-25 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-10-26 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-10-27 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-10-28 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-10-29 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-10-30 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-10-31 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-11-01 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-11-02 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-11-03 | $-1.92 | $7,648,750 | 3 / 3 |
| 2026-11-04 | $-1.92 | $7,648,750 | 3 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 4 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.